艾塞那肽对血压正常2型糖尿病患者血压的影响  

Effect of GLP-1 Receptor Agonist Exenatide on Blood Pressure in Type 2 Diabetic Patients with Normal Blood Pressure

作　　者：严力[1] 黄艾平[1] 张弛[2] 陈丹丹[2] 赵乃蕊[2] 李华珠[2] 杨晓春[2] 周桂莲[2] 冯晶[1] 王敏[2] 吴文字[2] 熊璞[2] 陈晶[2] 王霞[2] 

机构地区：[1]湖南省人民医院暨湖南省师范大学第一附属医院药学部,湖南长沙410005 [2]湖南省人民医院暨湖南省师范大学第一附属医院内分泌科,湖南长沙410005

出　　处：《医学临床研究》2013年第4期631-634,共4页Journal of Clinical Research

基　　金：湖南省科技计划项目

摘　　要：【目的】探讨GLP-1受体激动剂艾塞那肽对血压正常2型糖尿病患者血压的影响及其机制。【方法】选择自2009年11月至2010年10月本院内分泌科收治的57例无高血压疾病的2型糖尿病患者为研究对象，病程在7年以内。按照病程、体重指数、空腹及餐后C肽、血脂、原有治疗方案一一配对分成艾塞那肽治疗组（n=31）及对照组（n=26）。每月随访1次，测量收缩压及舒张压、体重、腰围、臀围，检测空腹餐后血糖、C肽等，对两组进行比较，探讨艾塞那肽治疗对血压正常2型糖尿病患者血压的影响。【结果】与治疗前比较，2型糖尿病患者接受艾塞那肽治疗后收缩压在整个随访期间下降，而舒张压在第2个月开始下降，差异有统计学意义（P〈0．05）。【结论】艾塞那肽可降低血压正常的2型糖尿病患者的收缩压及舒张压。[Objective]To explore the impact of GLP-1 receptor agonist exenatide on blood pressure（BP） in type 2 diabetics patients with normal BP and it mechanism. [Methods] A total of 57 cases of type 2 diabetes mellitus with- out hypertension admitted to endocrinology department in our hospital from Nov. 2009 to Oct. 2010 were chosen as the subjects. The disease course was less than 7 years. According to the course, body mass index（BMI）, fasting and postprandial C-peptide, blood lipids and original regimen, all patients were matched into exenatide group（ n ： 31） and control group（ n =26）. All patients were followed up once a month. Systolic blood pressure（SBP）, diastolic blood pressure（DBP）, weight, waist and hip circumference were measured. Fasting and postprandial blood glucose and C- peptide were determined. The parameters were compared between two groups. The impact of exenatide on BP in type 2 diabetic patients with normal BP was analyzed. [Results] Compared with before treatment, SBP in type 2 diabetic patients after exenatide treatment decreased during follow up, but DBP began to decrease from the second month, and there was significant difference（ P 〈0.05）. [Conclusion] Exenatide can decrease SBP and DBP in type 2 diabetic pa- tients with normal BP.

关 键 词：糖尿病 2型 药物疗法 血压 

分 类 号：R587.1[医药卫生—内分泌]